[Update of combined therapies with docetaxel for hormone-independent prostate cancer].
Zhonghua Nan Ke Xue
; 14(3): 264-7, 2008 Mar.
Article
em Zh
| MEDLINE
| ID: mdl-18488345
ABSTRACT
Hormone-independent prostate cancer (HIPC) is the end stage of prostate cancer, with a short median survival of 9-18 months for the patients. Two large phase III studies have demonstrated a survival advantage of docetaxel chemotherapy in HIPC patients. New combined protocols have been developed with promising results. These protocols propose a combination with docetaxel, chemotherapy, antiangiogenic agents, vaccine and biological drugs. This review focuses the progress achieved the combined therapies for HIPC.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Próstata
/
Taxoides
Idioma:
Zh
Ano de publicação:
2008
Tipo de documento:
Article